Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Pattern of bleeding in a large prospective cohort of haemophilia A patients: A three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study.

Khair K, Mazzucconi MG, Parra R, Santagostino E, Tsakiris DA, Hermans C, Oldenburg J, Spotts G, Steinitz-Trost K, Gringeri A.

Haemophilia. 2018 Jan;24(1):85-96. doi: 10.1111/hae.13361. Epub 2017 Oct 17.

PMID:
29044825
2.

Correction: Rapid Progressing Allele HLA-B35 Px Restricted Anti-HIV-1 CD8+ T Cells Recognize Vestigial CTL Epitopes.

Willberg CB, Garrison KE, Jones RB, Meiklejohn DA, Spotts G, Liegler TJ, Ostrowski MA, Karlsson AC, Hecht FM, Nixon DF.

PLoS One. 2016 Jul 25;11(7):e0160293. doi: 10.1371/journal.pone.0160293. eCollection 2016.

3.

Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.

Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, Ewenstein BM, Oh M, Spotts G.

Haemophilia. 2016 Jul;22(4):514-20. doi: 10.1111/hae.12905. Epub 2016 Mar 1.

4.

Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method.

Berntorp E, Spotts G, Patrone L, Ewenstein BM.

Biologics. 2014 Apr 5;8:115-27. doi: 10.2147/BTT.S53456. eCollection 2014. Review.

5.

Recruitment update of AHEAD.

Oldenburg J, Zimmermann R, Huth-Kühne A, Kurnik K, Klamroth R, Abraham I, Brondke H, Pirck M, Engl W, Reininger A, Spotts G.

Hamostaseologie. 2013;33 Suppl 1:S56-60.

PMID:
24344445
6.

T cells target APOBEC3 proteins in human immunodeficiency virus type 1-infected humans and simian immunodeficiency virus-infected Indian rhesus macaques.

Champiat S, Garrison KE, Raposo RA, Burwitz BJ, Reed J, Tandon R, York VA, Newman LP, Nimityongskul FA, Wilson NA, Almeida RR, Martin JN, Deeks SG, Rosenberg MG, Wiznia AA, Spotts GE, Pilcher CD, Hecht FM, Ostrowski MA, Sacha JB, Nixon DF.

J Virol. 2013 Jun;87(11):6073-80. doi: 10.1128/JVI.00579-12. Epub 2013 Mar 27.

7.

Prophylaxis and quality of life in patients with hemophilia A during routine treatment with ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] in Germany: a subgroup analysis of the ADVATE PASS post-approval, non-interventional study.

Pollmann H, Klamroth R, Vidovic N, Kriukov AY, Epstein J, Abraham I, Spotts G, Oldenburg J.

Ann Hematol. 2013 May;92(5):689-98. doi: 10.1007/s00277-013-1678-4. Epub 2013 Jan 17. Erratum in: Ann Hematol. 2013 Jul;92(7):1005.

PMID:
23324986
8.

Influence of HAART on alternative reading frame immune responses over the course of HIV-1 infection.

Champiat S, Raposo RA, Maness NJ, Lehman JL, Purtell SE, Hasenkrug AM, Miller JC, Dean H, Koff WC, Hong MA, Martin JN, Deeks SG, Spotts GE, Pilcher CD, Hecht FM, Kallas EG, Garrison KE, Nixon DF.

PLoS One. 2012;7(6):e39311. doi: 10.1371/journal.pone.0039311. Epub 2012 Jun 29.

9.

Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight.

Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW.

Blood. 2012 Jan 12;119(2):612-8. doi: 10.1182/blood-2011-07-360594. Epub 2011 Oct 31.

10.

Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.

Epstein J, Xiong Y, Woo P, Li-McLeod J, Spotts G.

Haemophilia. 2012 Mar;18(2):187-92. doi: 10.1111/j.1365-2516.2011.02636.x. Epub 2011 Aug 24.

PMID:
21883704
11.

Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection.

SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby CE, Loh L, Jones RB, Garrison KE, Martin JN, York VA, Spotts G, Reyes-Terán G, Ostrowski MA, Hecht FM, Deeks SG, Nixon DF.

J Virol. 2011 Jul;85(14):6977-85. doi: 10.1128/JVI.00179-11. Epub 2011 Apr 27.

12.

Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials.

Fischer K, Collins P, Björkman S, Blanchette V, Oh M, Fritsch S, Schroth P, Spotts G, Ewenstein B.

Haemophilia. 2011 May;17(3):433-8. doi: 10.1111/j.1365-2516.2010.02450.x. Epub 2011 Feb 7.

PMID:
21299740
13.

NK cells and CD1d-restricted NKT cells respond in different ways with divergent kinetics to IL-2 treatment in primary HIV-1 infection.

Kuylenstierna C, Snyder-Cappione JE, Loo CP, Long BR, Gonzalez VD, Michaëlsson J, Moll M, Spotts G, Hecht FM, Nixon DF, Sandberg JK.

Scand J Immunol. 2011 Feb;73(2):141-6. doi: 10.1111/j.1365-3083.2010.02484.x.

14.

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.

Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B.

Haemophilia. 2010 Nov;16(6):866-77. doi: 10.1111/j.1365-2516.2010.02332.x.

PMID:
20579113
15.

Rapid progressing allele HLA-B35 Px restricted anti-HIV-1 CD8+ T cells recognize vestigial CTL epitopes.

Willberg CB, Garrison KE, Jones RB, Meiklejohn DJ, Spotts G, Liegler TJ, Ostrowski MA, Karlsson AC, Hecht FM, Nixon DF.

PLoS One. 2010 Apr 21;5(4):e10249. doi: 10.1371/journal.pone.0010249. Erratum in: PLoS One. 2016;11(7):e0160293.

16.

Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM; Advate Clinical Program Group, Collins PW.

J Thromb Haemost. 2010 Apr;8(4):730-6. doi: 10.1111/j.1538-7836.2010.03757.x.

17.

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.

Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM.

J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836.2009.03703.x. Epub 2009 Nov 23.

18.

Immune escape mutations detected within HIV-1 epitopes associated with viral control during treatment interruption.

Schweighardt B, Wrin T, Meiklejohn DA, Spotts G, Petropoulos CJ, Nixon DF, Hecht FM.

J Acquir Immune Defic Syndr. 2010 Jan;53(1):36-46. doi: 10.1097/QAI.0b013e3181c4b885.

19.

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A.

Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B; rAHF-PFM Study Group.

J Thromb Haemost. 2009 Mar;7(3):413-20. doi: 10.1111/j.1538-7836.2008.03270.x. Epub 2008 Dec 20.

20.

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection.

Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA.

J Exp Med. 2008 Nov 24;205(12):2763-79. doi: 10.1084/jem.20081398. Epub 2008 Nov 10.

21.

Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.

Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM; rAHF-PFM Clinical Study Group.

J Thromb Haemost. 2008 Aug;6(8):1319-26. doi: 10.1111/j.1538-7836.2008.03032.x. Epub 2008 May 22.

22.

Immune reconstitution of CD56(dim) NK cells in individuals with primary HIV-1 infection treated with interleukin-2.

Michaëlsson J, Long BR, Loo CP, Lanier LL, Spotts G, Hecht FM, Nixon DF.

J Infect Dis. 2008 Jan 1;197(1):117-25. doi: 10.1086/524141.

23.

T cell responses to human endogenous retroviruses in HIV-1 infection.

Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, Chapman JM, Erickson AL, Agrawal A, Spotts G, Hecht FM, Rakoff-Nahoum S, Lenz J, Ostrowski MA, Nixon DF.

PLoS Pathog. 2007 Nov;3(11):e165.

24.

FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection.

Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM.

J Leukoc Biol. 2008 Feb;83(2):254-62. Epub 2007 Nov 2.

PMID:
17982112
25.

Human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T(EMRA) cells in early infection are linked to control of HIV-1 viremia and predict the subsequent viral load set point.

Northfield JW, Loo CP, Barbour JD, Spotts G, Hecht FM, Klenerman P, Nixon DF, Michaëlsson J.

J Virol. 2007 Jun;81(11):5759-65. Epub 2007 Mar 21.

26.

Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape.

Karlsson AC, Iversen AK, Chapman JM, de Oliviera T, Spotts G, McMichael AJ, Davenport MP, Hecht FM, Nixon DF.

PLoS One. 2007 Feb 21;2(2):e225.

27.

Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance.

Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM.

AIDS. 2007 Jan 11;21(2):239-41.

PMID:
17197817
28.

Elevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infection.

Norris PJ, Pappalardo BL, Custer B, Spotts G, Hecht FM, Busch MP.

AIDS Res Hum Retroviruses. 2006 Aug;22(8):757-62.

29.

Stability of ADVATE, Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion.

Fernandez M, Yu T, Bjornson E, Luu H, Spotts G.

Blood Coagul Fibrinolysis. 2006 Apr;17(3):165-71.

PMID:
16575253
30.

Expansion of CD1d-restricted NKT cells in patients with primary HIV-1 infection treated with interleukin-2.

Moll M, Snyder-Cappione J, Spotts G, Hecht FM, Sandberg JK, Nixon DF.

Blood. 2006 Apr 15;107(8):3081-3. Epub 2005 Dec 20.

31.

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.

Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED.

Semin Hematol. 2004 Jan;41(1 Suppl 2):1-16; discussion 16-8.

PMID:
15071785
33.

Dual DNA binding specificity of ADD1/SREBP1 controlled by a single amino acid in the basic helix-loop-helix domain.

Kim JB, Spotts GD, Halvorsen YD, Shih HM, Ellenberger T, Towle HC, Spiegelman BM.

Mol Cell Biol. 1995 May;15(5):2582-8.

34.
35.
36.

Partial characterization of a unique mitogenic activity secreted by rat Sertoli cells.

Lamb DJ, Spotts GS, Shubhada S, Baker KR.

Mol Cell Endocrinol. 1991 Aug;79(1-3):1-12.

PMID:
1936536
38.
39.

Characterization of a growth factor secreted by rat Sertoli cells in culture.

Holmes SD, Spotts G, Smith RG.

Prog Clin Biol Res. 1986;217A:389-92. No abstract available.

PMID:
3092246

Supplemental Content

Loading ...
Support Center